[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Pharmaceutical Contract Manufacturing Global Market - Forecast to 2025

March 2019 | 429 pages | ID: PC2B1B2010EEN
IQ4I Research & Consultancy Pvt. Ltd.

US$ 5,400.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Globally Pharmaceutical markets are showing rapid growth and in coming years expected to evolve further in the field of research and development, manufacturing and formulation due to rise in population, increasing in diseases like infectious diseases, oncology, cardiovascular disorders, rising healthcare expenditures, collaborations, merger and acquisitions. Pharmaceutical companies are increasing their dependence on contract manufacturing organizations due to lack of having well equipped manufacturing facilities, advanced technologies, high containment capabilities or though they have the facilities, due to insufficient time and to have backup manufacturing, pharmaceutical companies are outsourcing. This trend is favoring contract manufacturing service providers and is expected to increase the share in the pharmaceutical manufacturing market. Contract pharmaceutical manufacturing services are mainly focused on manufacturing of Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF). APIs based on molecule size are categorized into biologics/large and synthetic/small molecules. According to IQ4I analysis, synthetic molecules occupy major share of 65% to 70% and the biologics accounts for share of 30% to 35% in API market. One of the major reasons for increasing in synthetic API market is the availability of small molecule drugs for all the major diseases and large number of small molecule drugs in pipeline, which is expected to enter the market in coming years.

According to IQ4I analysis, the Pharmaceutical contract manufacturing global market is expected to grow at mid single digit CAGR to reach $95,904.9 million by 2025. Pharmaceutical contract manufacturing market based on product is segmented into API manufacturing and FDF manufacturing. API manufacturing market holds the largest share in 2018 and is expected to grow at mid single digit CAGR from 2018 to 2025 due to government initiatives, increase in a number of API manufacturers, increasing availability of APIs for all the diseases, aging population, rise in chronic diseases, research and manufacturing of new drugs and demand for generics. FDF manufacturing is the fastest growing segment with strong CAGR from 2018 to 2025, due to high profit margin for pharma contract manufacturers and most of the CMO companies in APAC regions are shifting from API to FDF manufacturing.

The API manufacturing market by customer base is sub segmented into Branded API manufacturing and Generic API manufacturing. The generic API manufacturing segment is accounted for the largest revenue in 2018 and is expected to grow at a strong CAGR from 2018 to 2025, due to the patent expiries of branded drugs, low cost of generic medicines. The branded API segment is projected to grow at a CAGR of 4.0% from 2018 to 2025.

The FDF manufacturing market by dosage form is classified into solid dosage form, injectable dosage form, and semi-solid liquid, gaseous dosage form. Solid dosage form is accounted for the largest revenue in 2018 and is expected to grow at a CAGR of 4.0% from 2018 to 2025, due to changing consumer demands, advent and progress of newer dosage forms and ever evolving regulations. The injectable dosage form is a fastest growing segment and expected to grow at a CAGR of 11.4% from 2018 to 2025 due to its direct infusion to the body, and onset of action of drugs is faster. Hence it is suitable for emergency conditions.

Pharmaceutical contract manufacturing by phase is segmented into commercial manufacturing and clinical manufacturing. Commercial manufacturing holds the highest revenue in 2018 and expected to grow at a mid single digit CAGR from 2018 to 2025, due to huge demand for commercial API production, patent expiry increases commercial manufacturing of API and FDF and increase in outsourcing of generic APIs. Whereas, clinical manufacturing is expected to grow at a high single digit CAGR from 2018 to 2025, due to increase in the number of pipeline drugs where 55-60% of the APIs are synthetic API, clinical phase 2 and 3 projects requiring cGMP facilities and increase in outsourcing by innovator pharma companies due to low cost manufacturing and shorter timelines. Also, clinical manufacturing play a significant role in securing client relationships that can lead to commercial scale manufacturing contracts.

Pharmaceutical contract manufacturing market by application is segmented as Oncology, Central nervous system, Cardiovascular disorder, Infectious diseases, Pulmonary disorders, Metabolic disorder, Gastrointestinal disorders, Musculoskeletal disorders, Genitourinary disorders, Endocrinology and other applications (acute pain, chronic pain and post-surgical, dental, ENT, autoimmune disorder). Among these applications, Infectious disease segment accounted for the largest revenue in 2018 due to increase in global HIV pandemic causes about one million deaths every year, emergence of severe acute respiratory syndrome (SARs) and viral hemorrhagic fever. The Oncology segment is a fastest growing application market during the forecasting period, due to increase in incidence of breast and lung cancer, increase in the usage of synthetic HPAPIs for cancer treatment, increase in geriatric population and FDA approvals.

Pharmaceutical contract manufacturing market by region is segmented as North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (China, India, Japan, and Others) and Rest of the World (Brazil, Rest of Latin America and Middle East & others). North America accounts for the largest revenue in 2018 and is expected to grow at a mid single digit CAGR from 2018 to 2025. In North America, U.S. and Canada are the most prominent countries in which U.S. occupies the largest revenue, due to expansion of regional market includes developed healthcare sector, availability of funds, increasing clinical trials, rising burden of cancer, increasing government focus on generic drugs, rising demands for specialty of drugs and technological advancements. Asia-Pacific region is expected to grow at a strong CAGR of 8.4% from 2018 to 2025. Mainly India and China are concentrated more due to low labor cost, regulatory relaxation, abundance availability of raw materials, infrastructure facility, rise in generic demands, increased production capabilities, the presence of large number of domestic and international players, and concentration of CMO companies.

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
  • North America
    • U.S.
    • Rest of North America
  • Europe
    • Germany
    • France
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Rest of APAC
  • Rest of the World (RoW)
    • Brazil
    • Rest of Latin America
    • Middle East and Others
1 EXECUTIVE SUMMARY

2 INTRODUCTION

2.1 KEY TAKEAWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
  2.6.1 MARKET SIZE ESTIMATION
  2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
  2.6.3 SECONDARY SOURCES
  2.6.4 PRIMARY SOURCES
  2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
  2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
  2.6.7 ASSUMPTIONS

3 MARKET ANALYSIS

3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
  3.3.1 DRIVERS AND OPPORTUNITIES
    3.3.1.1 Increased trend of outsourcing
    3.3.1.2 High uptake of small molecules across diverse therapeutics
    3.3.1.3 Patent expiration of small molecules drugs
    3.3.1.4 Advanced technologies in API and FDF manufacturing
    3.3.1.5 Increasing deals and investments
    3.3.1.6 Generics drive injectable market opportunity
    3.3.1.7 Increasing chronic and autoimmune diseases
    3.3.1.8 Increase in geriatric and aged population
  3.3.2 RESTRAINTS AND THREATS
    3.3.2.1 Contamination in the manufacturing
    3.3.2.2 Pricing pressure for pharmaceutical contract manufacturing
    3.3.2.3 Requirement of highly skilled technicians
    3.3.2.4 Increasing biologics approvals and adoption in disease management
    3.3.2.5 Stringent regulatory requirements
3.4 REGULATORY AFFAIRS
  3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
    3.4.1.1 ISO 9001: 2015 Quality management system
    3.4.1.2 ISO 14644-1 Clean room standards
  3.4.2 U.S.
  3.4.3 CANADA
  3.4.4 MEXICO
  3.4.5 EUROPE
  3.4.6 JAPAN
  3.4.7 CHINA
  3.4.8 INDIA
  3.4.9 AUSTRALIA
  3.4.10 SOUTH KOREA
  3.4.11 LATIN AMERICA
  3.4.12 MIDDLE EAST
3.5 PORTER’S FIVE FORCE ANALYSIS
  3.5.1 THREAT OF NEW ENTRANTS
  3.5.2 THREAT OF SUBSTITUTES
  3.5.3 BARGAINING POWER OF SUPPLIERS
  3.5.4 BARGAINING POWER OF BUYERS
  3.5.5 COMPETITIVE RIVALRY
3.6 SUPPLY CHAIN ANALYSIS
3.7 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
  3.7.1 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE ANALYSIS
  3.7.2 MARKET SHARE ANALYSIS OF API MANUFACTURING BY MAJOR PLAYERS
  3.7.3 MARKET SHARE ANALYSIS OF FDF MANUFACTURING BY MAJOR PLAYERS
3.8 TECHNOLOGICAL ADVANCEMENTS
  3.8.1 ADVANCED TECHNOLOGIES FOR API MANUFACTURING
  3.8.2 ADVANCED TECHNOLOGIES FOR FDF MANUFACTURING
3.9 DIFFERENTIATED CAPABILITIES
  3.9.1 HPAPI
    3.9.1.1 Selected top selling HPAPI
  3.9.2 CONTINUOUS FLOW MANUFACTURING
  3.9.3 CRYOGENIC MANUFACTURING PROCESS
3.10 CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING MARKET
3.11 PATENT EXPIRY AND ANDA APPROVALS
3.12 DRUG MASTER FILING (DMF)
3.13 COLLABORATION BETWEEN PHARMACEUTICAL COMPANIES AND CONTRACT MANUFACTURERS
3.14 COMPANIES ACQUISITION, MERGER AND INVESTMENTS
3.15 API PRICING
3.16 GLOBAL PHARMACEUTICAL API CMO PRODUCTION VOLUME
3.17 COST OF MANUFACTURING FACILITY
3.18 FDA APPROVED MANUFACTURING FACILITY
3.19 NOTICE OF INSPECTIONAL OBSERVATIONS (FORM 483)
3.20 CHINA V/S INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
  3.20.1 INDIA
  3.20.2 CHINA
3.21 PHARMACEUTICAL CONTRACT MANUFACTURERS REVENUE AND CAPABILITIES TABLE

4 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BY PRODUCT

4.1 INTRODUCTION
4.2 API MANUFACTURING
  4.2.1 BRANDED API MANUFACTURING
  4.2.2 GENERIC API MANUFACTURING
4.3 FINISHED DOSAGE FORM (FDF) MANUFACTURING
  4.3.1 SOLID DOSAGE FORMS
  4.3.2 INJECTABLES DOSAGE FORMS
  4.3.3 SEMISOLID, LIQUID AND GASEOUS DOSAGE FORMS

5 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BY PHASE

5.1 INTRODUCTION
5.2 CLINICAL MANUFACTURING
5.3 COMMERCIAL MANUFACTURING

6 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BY APPLICATION

6.1 INTRODUCTION
6.2 ONCOLOGY
6.3 CENTRAL NERVOUS SYSTEM
6.4 CARDIOVASCULAR DISORDERS
6.5 INFECTIOUS DISEASES
6.6 PULMONARY DISORDERS
6.7 METABOLIC DISORDERS
6.8 GASTROINTESTINAL DISORDERS
6.9 MUSCULOSKELETAL DISORDERS
6.10 GENITOURINARY DISORDERS
6.11 ENDOCRINOLOGY
6.12 OTHER APPLICATIONS

7 REGIONAL ANALYSIS

7.1 INTRODUCTION
7.2 NORTH AMERICA
  7.2.1 U.S.
  7.2.2 REST OF NORTH AMERICA
7.3 EUROPE
  7.3.1 GERMANY
  7.3.2 FRANCE
  7.3.3 ITALY
  7.3.4 REST OF EUROPE
7.4 APAC
  7.4.1 CHINA
  7.4.2 INDIA
  7.4.3 JAPAN
  7.4.4 REST OF APAC
7.5 ROW
  7.5.1 BRAZIL
  7.5.2 REST OF LATAM
  7.5.3 MIDDLE EAST & OTHERS

8 COMPETITIVE LANDSCAPE

8.1 INTRODUCTION
8.2 ACQUISITION, MERGER & COLLABORATION
8.3 EXPANSION AND INVESTMENT
8.4 REGULATORY APPROVAL
8.5 SERVICE LAUNCH AND OTHERS

9 MAJOR COMPANIES

9.1 ABBVIE INC.
  9.1.1 OVERVIEW
  9.1.2 FINANCIALS
  9.1.3 PRODUCT PORTFOLIO
  9.1.4 KEY DEVELOPMENTS
  9.1.5 BUSINESS STRATEGY
  9.1.6 SWOT ANALYSIS
9.2 AENOVA HOLDING GMBH
  9.2.1 OVERVIEW
  9.2.2 FINANCIAL
  9.2.3 PRODUCT PORTFOLIO
  9.2.4 KEY DEVELOPMENTS
  9.2.5 BUSINESS STRATEGY
  9.2.6 SWOT ANALYSIS
9.3 ALBANY MOLECULAR RESEARCH INC.
  9.3.1 OVERVIEW
  9.3.2 FINANCIALS
  9.3.3 PRODUCT PORTFOLIO
  9.3.4 KEY DEVELOPMENTS
  9.3.5 BUSINESS STRATEGY
  9.3.6 SWOT ANALYSIS
9.4 ALMAC GROUP
  9.4.1 OVERVIEW
  9.4.2 FINANCIALS
  9.4.3 PRODUCT PORTFOLIO
  9.4.4 KEY DEVELOPMENTS
  9.4.5 BUSINESS STRATEGY
  9.4.6 SWOT ANALYSIS
9.5 CAMBREX CORPORATION
  9.5.1 OVERVIEW
  9.5.2 FINANCIALS
  9.5.3 PRODUCT PORTFOLIO
  9.5.4 KEY DEVELOPMENTS
  9.5.5 BUSINESS STRATEGY
  9.5.6 SWOT ANALYSIS
9.6 FAMAR S.A.
  9.6.1 OVERVIEW
  9.6.2 FINANCIALS
  9.6.3 PRODUCT PORTFOLIO
  9.6.4 KEY DEVELOPMENTS
  9.6.5 BUSINESS STRATEGY
  9.6.6 SWOT ANALYSIS
9.7 GLAXOSMITHKLINE PLC
  9.7.1 OVERVIEW
  9.7.2 FINANCIALS
  9.7.3 PRODUCT PORTFOLIO
  9.7.4 KEY DEVELOPMENTS
  9.7.5 BUSINESS STRATEGY
  9.7.6 SWOT ANALYSIS
9.8 LONZA GROUP LTD
  9.8.1 OVERVIEW
  9.8.2 FINANCIALS
  9.8.3 PRODUCT PORTFOLIO
  9.8.4 KEY DEVELOPMENTS
  9.8.5 BUSINESS STRATEGY
  9.8.6 SWOT ANALYSIS
9.9 THERMO FISHER SCIENTIFIC (PATHEON N.V.)
  9.9.1 OVERVIEW
  9.9.2 FINANCIALS
  9.9.3 PRODUCT PORTFOLIO
  9.9.4 KEY DEVELOPMENTS
  9.9.5 BUSINESS STRATEGY
  9.9.6 SWOT ANALYSIS
9.10 PFIZET INC (PFIZER CENTERONE)
  9.10.1 OVERVIEW
  9.10.2 FINANCIALS
  9.10.3 PRODUCT PORTFOLIO
  9.10.4 KEY DEVELOPMENTS
  9.10.5 BUSINESS STRATEGY
  9.10.6 SWOT ANALYSIS
9.11 RECIPHARM AB
  9.11.1 OVERVIEW
  9.11.2 FINANCIALS
  9.11.3 PRODUCT PORTFOLIO
  9.11.4 KEY DEVELOPMENTS
  9.11.5 BUSINESS STRATEGY
  9.11.6 SWOT ANALYSIS
9.12 WUXI STA PHARMACEUTICALS LTD (WUXI APPTEC)
  9.12.1 OVERVIEW
  9.12.2 FINANCIALS
  9.12.3 PRODUCT PORTFOLIO
  9.12.4 KEY DEVELOPMENTS
  9.12.5 BUSINESS STRATEGY
  9.12.6 SWOT ANALYSIS

LIST OF TABLES

TABLE 1 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 2 CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING REVENUE, BY MARKET, (2017-2025) ($MN)
TABLE 3 PATENT EXPIRY OF SYNTHETIC SMALL MOLECULE DRUGS, (2016 – 2021)
TABLE 4 ANDA APPROVALS, (2017 – 2018)
TABLE 5 SMALL MOLECULES API DMF FILED BY COMPANIES, (2017 – 2018)
TABLE 6 COLLABORATIONS, (2016 – 2019)
TABLE 7 ACQUISITION AND MERGER, (2017 – 2019)
TABLE 8 INVESTEMENTS, (2016 – 2018)
TABLE 9 API PRICING OF MAJOR SMALL MOLECULES
TABLE 10 GLOBAL PHARMACEUTICALS API REVENUE ($MN), AVERAGE SELLING PRICE ($/KG) AND PRODUCTION IN TONS, BY APPLICATION (2018)
TABLE 11 GLOBAL PHARMACEUTICAL API PRODUCTION, BY APPLICATION, (2017-2025) (TONS)
TABLE 12 GLOBAL PHARMACEUTICAL VOLUME AND UTILIZATION, CMO VOLUME AND UTILIZATION, (2017-2025) (MILLION LITRES)
TABLE 13 GLOBAL PHARMACEUTICAL VOLUME AND UTILIZATION, CMO VOLUME AND UTILIZATION, (2017-2025) (MILLION LITRES)
TABLE 14 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY PRODUCT, (2017-2025) ($MN)
TABLE 15 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 16 API MANUFACTURING GLOBAL MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
TABLE 17 API MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 18 BRANDED API MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 19 GENERIC API MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 20 FDF MANUFACTURING GLOBAL MARKET REVENUE, BY DOSAGE FORM, (2017-2025) ($MN)
TABLE 21 FDF MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 22 SOLID DOSAGE FORMS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 23 INJECTABLES DOSAGE FORMS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 24 SEMISOLID, LIQUID AND GASEOUS DOSAGE FORMS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 25 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY PHASE, (2017-2025) ($MN)
TABLE 26 CLINICAL MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 27 COMMERCIAL MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 28 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
TABLE 29 ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 30 CENTRAL NERVOUS SYSTEM GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 31 CARDIOVASCULAR DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 32 INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 33 PULMONARY DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 34 METABOLIC DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 35 GASTROINTESTINAL DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 36 MUSCULOSKELETAL DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 37 GENITOURINARY DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 38 ENDOCRINOLOGY GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 39 OTHER APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 40 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 41 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2017-2025) ($MN)
TABLE 42 NORTH AMERICA API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
TABLE 43 NORTH AMERICA FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2017-2025) ($MN)
TABLE 44 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2017-2025) ($MN)
TABLE 45 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
TABLE 46 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
TABLE 47 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2017-2025) ($MN)
TABLE 48 EUROPE API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
TABLE 49 EUROPE FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2017-2025) ($MN)
TABLE 50 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2017-2025) ($MN)
TABLE 51 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
TABLE 52 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
TABLE 53 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2017-2025) ($MN)
TABLE 54 APAC API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
TABLE 55 APAC FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2017-2025) ($MN)
TABLE 56 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2017-2025) ($MN)
TABLE 57 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
TABLE 58 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
TABLE 59 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2017-2025) ($MN)
TABLE 60 ROW API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
TABLE 61 ROW FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2017-2025) ($MN)
TABLE 62 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2017-2025) ($MN)
TABLE 63 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
TABLE 64 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
TABLE 65 ACQUISITION, MERGER & COLLABORATION (2016-2018)
TABLE 66 EXPANSION AND INVESTMENT (2016-2018)
TABLE 67 REGULATORY APPROVAL (2017-2018)
TABLE 68 SERVICE LAUNCH AND OTHERS (2016-2018)
TABLE 69 ABBVIE INC.: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
TABLE 70 ABBVIE INC.: TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
TABLE 71 ABBVIE INC.: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
TABLE 72 CAMBREX: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
TABLE 73 CAMBREX : TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
TABLE 74 GLAXOSMITHKLINE PLC: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
TABLE 75 GLAXOSMITHKLINE PLC: TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
TABLE 76 GSK :TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
TABLE 77 LONZA GROUP: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
TABLE 78 LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
TABLE 79 LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
TABLE 80 THERMO FISHER SCIENTIFIC: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
TABLE 81 THERMO FISHER SCIENTIFIC: TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
TABLE 82 THERMO FISHER SCIENTIFIC: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
TABLE 83 PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
TABLE 84 PFIZER INC: TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
TABLE 85 PFIZER INC: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
TABLE 86 RECIPHARM AB: TOTAL REVENUE AND R&D EXPENSES (2016-2017) ($MN)
TABLE 87 RECIPHARM AB: TOTAL REVENUE, BY SEGMENT (2015-2017) ($MN)
TABLE 88 RECIPHARM AB: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)

LIST OF FIGURES

FIGURE 1 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION (2017-2025) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET
FIGURE 3 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SEGMENTATION
FIGURE 7 MARKET DYNAMICS
FIGURE 8 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 9 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 10 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2018 (%)
FIGURE 11 API MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2018 (%)
FIGURE 12 FDF MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2018 (%)
FIGURE 13 CONTRACT MANUFACTURING COMPANY CAPABILITIES
FIGURE 14 CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING REVENUE, BY MARKET, 2018 ($MN)
FIGURE 15 PATENT EXPIRY OF SMALL MOLECULES (2016-2021)
FIGURE 16 PATENT EXPIRY (2019-2021) AND ANDA APPROVALS (2017-2018), BY APPLICATION SHARE (%)
FIGURE 17 PHARMACEUTICAL API PRODUCTION BY APPLICATION (2018), IN-HOUSE V/S CMO (2017 – 2025) (TONS) AND GLOBAL MANUFACTURING CAPACITIES (2018) (LITRES)
FIGURE 18 GLOBAL PHARMACEUTICAL API CMO PRODUCTION (2017 – 2025) (TONS), API CMO MARKET SHARE BY REGION (2018) (%)
FIGURE 19 FDA APPROVED MANUFACTURING FACILITY BY COUNTRY (NO’S)
FIGURE 20 INDIA V/S CHINA
FIGURE 21 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY PRODUCT (2018 V/S 2025) (%)
FIGURE 22 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
FIGURE 23 API MANUFACTURING GLOBAL MARKET SHARE, BY CUSTOMER BASE (2018 V/S 2025) (%)
FIGURE 24 API MANUFACTURING GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
FIGURE 25 FDF MANUFACTURING GLOBAL MARKET SHARE, BY DOSAGE FORM, (2018 V/S 2025) (%)
FIGURE 26 FDF MANUFACTURING GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
FIGURE 27 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY PHASE (2018 V/S 2025) (%)
FIGURE 28 CLINICAL MANUFACTURING GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
FIGURE 29 COMMERCIAL MANUFACTURING GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
FIGURE 30 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY APPLICATION (2018 V/S 2025) (%)
FIGURE 31 CARDIOVASCULAR DISORDERS GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
FIGURE 32 PULMONARY DISORDERS GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
FIGURE 33 METABOLIC DISORDERS GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
FIGURE 34 GASTROINTESTINAL DISORDERS GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
FIGURE 35 ENDOCRINOLOGY GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
FIGURE 36 OTHER APPLICATION GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
FIGURE 37 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION (2017-2025) ($MN), CAGR (%)
FIGURE 38 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY GEOGRAPHY (2018) (%)
FIGURE 39 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT, API AND FDF MANUFACTURING BY CUSTOMER BASE AND DOSAGE FORM (2018 V/S 2025) (%)
FIGURE 40 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PHASE (2018 V/S 2025) (%)
FIGURE 41 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
FIGURE 42 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2018 V/S 2025) (%)
FIGURE 43 U.S. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
FIGURE 44 U.S. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
FIGURE 45 REST OF NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
FIGURE 46 REST OF NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
FIGURE 47 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT, API AND FDF MANUFACTURING BY CUSTOMER BASE AND DOSAGE FORM (2018 V/S 2025) (%)
FIGURE 48 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PHASE (2018 V/S 2025) (%)
FIGURE 49 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
FIGURE 50 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2018 V/S 2025) (%)
FIGURE 51 GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
FIGURE 52 GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
FIGURE 53 FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
FIGURE 54 FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
FIGURE 55 ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
FIGURE 56 ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
FIGURE 57 REST OF EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
FIGURE 58 REST OF EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
FIGURE 59 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT, API AND FDF MANUFACTURING BY CUSTOMER BASE AND DOSAGE FORM (2018 V/S 2025) (%)
FIGURE 60 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PHASE (2018 V/S 2025) (%)
FIGURE 61 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
FIGURE 62 APAC PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2018 V/S 2025) (%)
FIGURE 63 CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
FIGURE 64 CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
FIGURE 65 INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
FIGURE 66 INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
FIGURE 67 JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
FIGURE 68 JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
FIGURE 69 REST OF APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
FIGURE 70 REST OF APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
FIGURE 71 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT, API AND FDF MANUFACTURING BY CUSTOMER BASE AND DOSAGE FORM (2018 V/S 2025) (%)
FIGURE 72 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PHASE (2018 V/S 2025) (%)
FIGURE 73 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
FIGURE 74 ROW PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2018 V/S 2025) (%)
FIGURE 75 BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
FIGURE 76 BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
FIGURE 77 REST OF LATAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
FIGURE 78 REST OF LATAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
FIGURE 79 MIDDLE EAST & OTHERS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2018 V/S 2025) ($MN)
FIGURE 80 MIDDLE EAST & OTHERS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
FIGURE 81 KEY GROWTH STRATEGIES, (2016-2018)
FIGURE 82 SWOT: ABBVIE CONTRACT MANUFACTURING.
FIGURE 83 SWOT: AENOVA HOLDING GMBH
FIGURE 84 SWOT: AMRI
FIGURE 85 SWOT: ALMAC
FIGURE 86 SWOT: CAMBREX CORPORATION
FIGURE 87 SWOT: FAMAR S.A.
FIGURE 88 SWOT: GLAXOSMITHKLINE PLC
FIGURE 89 SWOT: LONZA GROUP
FIGURE 90 SWOT: PATHEON N.V.
FIGURE 91 SWOT: PFIZER CENTREONE
FIGURE 92 SWOT: RECIPHARM
FIGURE 93 SWOT: WUXI STA


More Publications